Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EPS (Weighted Average and Diluted) (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$3.51 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 17.0% year-over-year to -$3.51; the TTM value through Dec 2025 reached -$13.48, down 29.87%, while the annual FY2025 figure was -$13.48, 32.03% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$3.51 in Q4 2025 per PRAX's latest filing, down from -$3.37 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.78 in Q3 2023 and bottomed at -$65.86 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$7.01, with a median of -$2.92 recorded in 2024.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 181.25% in 2023, down 600.66% in 2023.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$65.86 in 2022, then surged by 97.02% to -$1.96 in 2023, then crashed by 53.06% to -$3.0 in 2024, then fell by 17.0% to -$3.51 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$3.51 in Q4 2025, -$3.37 in Q3 2025, and -$3.31 in Q2 2025.